Financial calendar for Zealand Pharma in 2018
Company announcement - No. 52/2017
Financial calendar for Zealand Pharma in 2018
Copenhagen, November 30, 2017 - Zealand Pharma A/S ("ZEAL") announces the following dates for the company's planned financial reporting in 2018:
7 March Full year announcement and Annual Report 2017 16 May Interim report for the first three months of 201816 August Interim report for 1st half 201815 November Interim report for the first 9 months of 2018
Zealand's Annual General Meeting will be held on April 19, 2018.
For further information, please contact:
Mats Blom, Executive Vice President and Chief Financial OfficerTel.: +45 31 53 79 73, e-mail: [email protected]
About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim as well as a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases. Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow us on Twitter @ZealandPharma or LinkedIn.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/4dbcd952-530a-49a5-9400-3021a64a8360
Source: Zealand Pharma A/SSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zealand Pharma - Transactions related to share buy-back program (week 33, 2026)
- Elseland Unveils 20 Games Created with AI, Advancing AI Game Development at Scale
- Video - CEO Clips: Metalero Mining Advances District-Scale Exploration Next to a World-Class Silver Mine
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share